Dasatinib + Quercetin
Dasatinib + Quercetin Senolytic Combination
Pharmaceutical senolytic combination that selectively clears senescent (zombie) cells. Dasatinib (tyrosine kinase inhibitor) targets senescent fat cell progenitors while quercetin targets senescent endothelial cells. The most studied senolytic drug combination in human trials.
📊 Evidence by Outcome
Senescent cell clearance
3 studies • Consistency: Moderate • Effect: Moderate
Reduced tissue inflammation
3 studies • Consistency: Moderate • Effect: Moderate
Improved physical function
3 studies • Consistency: Moderate • Effect: Moderate
Potential age reversal markers
3 studies • Consistency: Moderate • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 2 Citations
First Human Senolytic Trial
••2019
Key Finding: D+Q reduced senescent cell burden and improved physical function in patients with idiopathic pulmonary fibrosis
Senolytics in Diabetic Kidney Disease
••2020
Key Finding: D+Q decreased senescent cell markers, reduced inflammation, and improved adipose tissue function in diabetic kidney disease patients
Citations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
$50-200 per cycle
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.